Top Story

Johnson & Johnson acquires Intra-Cellular for $14.6bn

Johnson & Johnson acquires Intra-Cellular for $14.6bn

14-Jan-2025

|

By Clara Rodriguez Fernandez

Editor's Choice

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

22-Nov-2024

Headlines

Scope Summit finalists to fight for awards in site innovation and...

Verdiva Bio launches with $411m in funding to advance obesity drugs

India’s Anthem Biosciences plans $397m IPO

Orbis Medicines bags €90 million Series A to develop oral...

Gilead recruits Terray in AI-driven drug discovery pact

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

→

In focus

Eli Lilly invests $3bn in injectable drug manufacturing facility

10-Dec-2024 By Clara Rodriguez Fernandez

Insights into creating an inhaler product through jet milling

Paid for and in partnership with Lonza Small Molecules

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

07-Jan-2025 By Clara Rodriguez Fernandez

AI transforms route scouting for faster drug synthesis

Paid for and in partnership with Lonza Small Molecules

Featured

Insight

Verdiva Bio launches with $411m in funding to advance obesity drugs

By Clara Rodriguez Fernandez

Verdiva Bio launches with $411m in funding to advance obesity drugs

Clinical trials & development

→

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

07-Jan-2025

By Clara Rodriguez Fernandez

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

19-Dec-2024

By Clara Rodriguez Fernandez

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results

AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results

10-Dec-2024

By Larissa Warneck-Silvestrin

Partner insightMore →

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd.

Accurate determination of resin substitution in solid phase peptide synthesis

Content provided by Almac Group

Reliability, scale, and security of supply

Content provided by Univar Solutions USA

Markets & regulatory news

→

India’s Anthem Biosciences plans $397m IPO

India’s Anthem Biosciences plans $397m IPO

09-Jan-2025

By Jonathan Smith

Gilead recruits Terray in AI-driven drug discovery pact

Gilead recruits Terray in AI-driven drug discovery pact

19-Dec-2024

By Jonathan Smith

AbbVie acquires Roche immune drug spinout in $200 million deal

AbbVie acquires Roche immune drug spinout in $200 million deal

17-Dec-2024

By Clara Rodriguez Fernandez

Adragos Pharma snaps up Baccinex to expand CDMO network

Adragos Pharma snaps up Baccinex to expand CDMO network

26-Nov-2024

Drug delivery & innovation

→

Verdiva Bio launches with $411m in funding to advance obesity drugs

Verdiva Bio launches with $411m in funding to advance obesity drugs

09-Jan-2025

By Clara Rodriguez Fernandez

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

06-Jan-2025

By Jonathan Smith

Eli Lilly invests $3bn in injectable drug manufacturing facility

Eli Lilly invests $3bn in injectable drug manufacturing facility

10-Dec-2024

By Clara Rodriguez Fernandez

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

Brixton Biosciences: Drug-free pain relief for knee osteoarthritis

22-Nov-2024

Expand your knowledge

Industry Newsletters

Choose from regular, topic-based and special edition briefings

Resource centre

Discover cutting edge insight from our partners

Events & webinars

Explore our programme of live & on-demand content